Hubbry Logo
5-HT2A receptor5-HT2A receptorMain
Open search
5-HT2A receptor
Community hub
5-HT2A receptor
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
5-HT2A receptor
5-HT2A receptor
5-HT2A receptor
View on Wikipedia
from Wikipedia

HTR2A
Identifiers
AliasesHTR2A, 5-HT2A, HTR2, 5-hydroxytryptamine receptor 2A
External IDsOMIM: 182135; MGI: 109521; HomoloGene: 68073; GeneCards: HTR2A; OMA:HTR2A - orthologs
Orthologs
SpeciesHumanMouse
Entrez

3356

15558

Ensembl

ENSG00000102468

ENSMUSG00000034997

UniProt

P28223

P35363

RefSeq (mRNA)

NM_001165947
NM_000621
NM_001378924

NM_172812

RefSeq (protein)

NP_000612
NP_001159419
NP_001365853

NP_766400

Location (UCSC)Chr 13: 46.83 – 46.9 Mbn/a
PubMed search[2][3]
Wikidata
View/Edit HumanView/Edit Mouse

The 5-HT2A receptor is a subtype of the 5-HT2 receptor that belongs to the serotonin receptor family and functions as a G protein-coupled receptor (GPCR).[4] It is a cell surface receptor[5] that activates multiple intracellular signalling cascades.[6] Like all 5-HT2 receptors, the 5-HT2A receptor is coupled to the Gq/G11 signaling pathway. It is the primary excitatory receptor subtype among the serotonin-responsive GPCRs. The 5-HT2A receptor was initially noted for its central role as the primary target of serotonergic psychedelic drugs such as LSD and psilocybin mushrooms. It later regained research prominence when found to mediate, at least in part, the effects of many antipsychotic drugs, particularly atypical antipsychotics.

History

[edit]

The serotonin receptors were split into two classes by John Gaddum and Picarelli in 1957 when it was discovered that some of the serotonin-induced changes in the gut could be blocked by morphine, while the remainder of the response was inhibited by dibenzyline (phenoxybenzamine), leading to the naming of M and D receptors, respectively.[7][8] The 5-HT2A receptor is thought to correspond to what was originally described as D subtype of serotonin receptors by Gaddum and Picarelli.[7][8]

In the era before molecular cloning, when radioligand binding and displacement was the only major tool, spiperone and LSD were shown to label two different 5-HT receptors, and neither of them displaced morphine, leading to naming of the 5-HT1, 5-HT2 and 5-HT3 receptors, corresponding to high affinity sites from LSD, spiperone and morphine, respectively.[9] Later, it was shown that the 5-HT2 receptor was very close to the 5-HT1C receptor and they were thus were grouped together, renaming the 5-HT2 receptor into 5-HT2A receptor and the 5-HT1C reeptor into the 5-HT2C receptor. Thus, the 5-HT2 receptor family is composed of three separate molecular entities: the 5-HT2A (formerly known as 5-HT2 or D), the 5-HT2B (formerly known as 5-HT2F) and the 5-HT2C (formerly known as 5-HT1C) receptors.[10]

The serotonin 5-HT2A receptor was identified via radioligand binding in 1978 by Leysen and colleagues.[11][12] Peroutka and Snyder identified two distinct serotonin receptors and named them the 5-HT1 receptor and 5-HT2 receptor in 1979.[13][14] Later, both of these receptors were found to have several subtypes, including the serotonin 5-HT2A receptor.[13] The serotonin 5-HT2A receptor was characterized as a membrane protein by Wouters and colleagues in 1985.[11][15] The gene encoding the rat serotonin 5-HT2A receptor, HTR2A, was cloned in 1988 by Pritchett and colleagues.[11][16] The human gene was cloned by Branchek and colleagues in 1990.[13][17]

Gene

[edit]
Chromosome 13.

The 5-HT2A receptors is coded by the HTR2A gene. In humans the gene is located on chromosome 13. The gene has previously been called just HTR2 until the description of two related genes HTR2B and HTR2C. Several interesting polymorphisms have been identified for HTR2A: A-1438G (rs6311), C102T (rs6313), and His452Tyr (rs6314). Many more polymorphisms exist for the gene. A 2006 paper listed 255.[18][19]

Probable role in fibromyalgia as the T102C polymorphisms of the gene 5HT2A were common in fibromyalgia patients.[20]

Human HTR2A gene is thought to consist of 3 introns and 4 exons and to overlap with human gene HTR2A-AS1 which consists of 18 exons.[21] There are over 200 organisms that have orthologs with the human HTR2A. Currently, the best documented orthologs for HTR2A gene are the mouse,[22] and zebrafish.[23] There are 8 paralogs for the HTR2A gene. The HTR2A gene is known to interact and activate G-protein genes such as GNA14, GNAI1, GNAI3, GNAQ, and GNAZ.[24] These interactions are critical for cell signaling[25][26] and homeostasis[27] in many organisms.[28]

In human brain tissue, regulation of HTR2A varies depending on the region:[21] frontal cortex, amygdala, thalamus, brain stem and cerebellum. In a paper from 2016, they found that HTR2A undergoes a variety of different splicing events, including utilization of alternative splice acceptor sites, exon skipping, rare exon usage, and intron retention.[21]

Transcriptional regulation

[edit]

There are a few mechanisms of regulation for HTR2A gene such regulated by DNA methylation at particular transcript binding sites.[29][30] Another mechanism for the correct regulation of gene expression is achieved through alternative splicing. This is a co-transcriptional process, which allows the generation of multiple forms of mRNA transcript from a single coding unit and is emerging as an important control point for gene expression. In this process, exons or introns can be either included or excluded from precursor-mRNA resulting in multiple mature mRNA variants.[31] These mRNA variants result in different isoforms which may have antagonistic functions or differential expression patterns, yielding plasticity and adaptability to the cells.[32] One study found that the common genetic variant rs6311 regulates expression of HTR2A transcripts containing the extended 5' UTR.[21]

Tissue distribution

[edit]

5-HT2A is expressed widely throughout the central nervous system (CNS).[33] It is expressed near most of the serotonergic terminal rich areas, including neocortex (mainly prefrontal, parietal, and somatosensory cortex) and the olfactory tubercle [citation needed]. Especially high concentrations of this receptor on the apical dendrites of pyramidal cells in layer V of the cortex may modulate cognitive processes, working memory, and attention[34][35][36] by enhancing glutamate release followed by a complex range of interactions with the 5-HT1A,[37] GABAA,[38] adenosine A1,[39] AMPA,[40] mGluR2/3,[41] mGlu5,[42] and OX2 receptors.[43][44] In the rat cerebellum, the protein has also been found in the Golgi cells of the granular layer,[45] and in the Purkinje cells.[46][47]

In the periphery, it is highly expressed in platelets and many cell types of the cardiovascular system, in fibroblasts, and in neurons of the peripheral nervous system. Additionally, 5-HT2A mRNA expression has been observed in human monocytes.[48] Whole-body distribution of the 5-HT2A/2C receptor agonist, [11C]Cimbi-36 show uptake in several internal organs and brown adipose tissue (BAT), but it is not clear if this represents specific 5-HT2A receptor binding.[49]

Structure

[edit]

The 5-HT2A receptor is a member of the class A (rhodopsin-like) G protein-coupled receptor (GPCR) family, characterized by seven transmembrane α-helices connected by extracellular and intracellular loops.[50][51] Its ligand-binding pocket is composed of two adjacent subpockets: the orthosteric binding pocket (OBP) and an extended binding pocket (EBP), with a unique side-extended cavity near the orthosteric site that distinguishes it from related receptors.[52][53] Ligands are anchored primarily through a conserved aspartate residue (D155^3.32) that interacts with their charged amine groups, while additional interactions involve hydrophobic contacts and hydrogen bonds with residues in both the OBP and EBP.[53][54] Structural studies reveal that the receptor undergoes significant conformational changes upon activation, particularly in transmembrane helices 3 and 6, which facilitate G protein coupling and signal transduction.[50][53] The extracellular ligand-binding pocket is closed by a flexible "lid," and the intracellular region includes a short helix (H8) stabilized by π-stacking interactions, both of which contribute to the receptor's dynamic conformational landscape.[53] These structural features underlie the receptor's ability to recognize diverse ligands and mediate complex signaling behaviors.

The cryo-EM structures of the serotonin 5-HT2A receptor with a variety of serotonin 5-HT2A receptor agonists, including the tryptamines serotonin (neurotransmitter and endogenous agonist), psilocin (psychedelic), and dimethyltryptamine (DMT) (psychedelic), the lysergamides LSD (psychedelic) and 2-bromo-LSD (BOL-148) (non-hallucinogenic), and the phenethylamines mescaline (psychedelic) and RS130-180 (β-arrestin-biased agonist with unknown hallucinogenic potential), have been solved and published by Bryan Roth and colleagues.[55][56]

Function

[edit]

The 5-HT2A receptor is a subtype of serotonin receptor that plays a critical role in the central nervous system, particularly in regions involved in cognition, learning, and memory.[57] It is highly expressed in the cerebral cortex, especially in layer V pyramidal neurons and certain interneurons, where it modulates thalamocortical information processing and may influence gamma oscillations, which are important for sensory integration and perception.[58] Functionally, the 5-HT2A receptor is a G protein-coupled receptor (GPCR) that primarily signals through the phospholipase C (PLC) pathway, leading to the production of inositol triphosphate (IP3) and diacylglycerol, but it can also activate other signaling cascades such as arachidonic acid and 2-arachidonylglycerol pathways.[58] Notably, the receptor exhibits "functional selectivity," meaning different ligands can differentially activate these signaling pathways, which is relevant for the distinct effects of hallucinogens, antipsychotics, and antidepressants that target the receptor.[58][54] Activation of the 5-HT2A receptor by agonists is associated with enhanced cognition and hallucinogenic effects, while antagonists have antipsychotic and antidepressant properties.[57] Dysregulation of 5-HT2A receptor function has been implicated in psychiatric disorders such as depression, schizophrenia, and drug addiction.[57] Additionally, the receptor undergoes unique regulatory processes, including desensitization and internalization that are partly independent of β-arrestin, further distinguishing it from other GPCRs and influencing its response to long-term pharmacological modulation.[58]

Signaling cascade

[edit]

The 5-HT2A receptor is known primarily to couple to the Gαq signal transduction pathway. Upon receptor stimulation with agonist, Gαq and β-γ subunits dissociate to initiate downstream effector pathways. Gαq stimulates phospholipase C (PLC) activity, which subsequently promotes the release of diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn stimulate protein kinase C (PKC) activity and Ca2+ release.[59]

Effects

[edit]

Physiological processes mediated by the receptor include:

Ligands

[edit]

Agonists

[edit]
Further information: List of miscellaneous 5-HT2A receptor agonists

Activation of the 5-HT2A receptor is necessary for the effects of the "classic" psychedelics like LSD, psilocin and mescaline, which act as full or partial agonists at this receptor, and represent the three main classes of 5-HT2A agonists, the ergolines, tryptamines and phenethylamines, respectively. A very large family of derivatives from these three classes has been developed, and their structure-activity relationships have been extensively researched.[73][74] Agonists acting at 5-HT2A receptors located on the apical dendrites of pyramidal cells within regions of the prefrontal cortex are believed to mediate hallucinogenic activity. Some findings reveal that psychoactive effects of classic psychedelics are mediated by the receptor heterodimer 5-HT2A–mGlu2 and not by monomeric 5-HT2A receptors.[75][76][60] However, newer research suggests that 5HT2A and mGlu2 receptors do not physically associate with each other, so the former findings have questionable relevance.[77] Agonists enhance dopamine in PFC,[36] enhance memory and play an active role in attention and learning.[78][79]

Serotonin 5-HT2A receptor agonists include serotonergic psychedelics[80] and non-hallucinogenic agents.[81][82] Psychedelics have widely been encountered as recreational drug or drugs of misuse, with potential clinical consequences such as overdose, hospitalization, bad trips and worsened mental health, and rare adverse effects such as seizures, psychosis, and hallucinogen persisting perception disorder (HPPD).[83][84] On the other hand, psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are under development as novel treatments for psychiatric disorders like depression, anxiety, and addiction as well as other conditions like cluster headaches.[85][86][87][88][89] Both psychedelics and non-hallucinogenic serotonin 5-HT2A receptor agonists are claimed to act as psychoplastogens and this might be involved in their therapeutic effects.[88][90][91]

Anti-inflammatory effects

[edit]

Various serotonergic psychedelics, acting as serotonin 5-HT2A receptor agonists, have been found to be highly potent and efficacious anti-inflammatory and immunomodulatory agents in preclinical research (i.e., animal and in-vitro studies).[92][93][94][95][96][97][98] In contrast to corticosteroids however, psychedelics with anti-inflammatory effects do not appear to suppress the immune system.[92][93] Some psychedelics have been found to be far more potent in their anti-inflammatory effects than in their psychedelic effects.[94][95] For instance, (R)-DOI is 30- to >50-fold more potent in producing anti-inflammatory effects than in producing psychedelic-like behavioral effects in animal research.[94][95][93] Psilocin, the active form of psilocybin, has similar anti-inflammatory potency as (R)-DOI.[93][94][98]

The potencies of psychedelics and other serotonin 5-HT2A receptor agonists as anti-inflammatory drugs vary, with 2C-I, DOIB, 2C-B, 4-HO-DiPT, DOI, 2,5-DMA, DOET, DOM, psilocin, and 2C-H being highly potent and fully efficacious anti-inflammatories; TMA-2, 2C-B-Fly, TCB-2, ETH-LAD, LSD, and 2C-T-33 being partially efficacious anti-inflammatories; and lisuride, 1-methylpsilocin, 5-MeO-DMT, and DMT having negligible efficacy.[93][98] Both non-hallucinogenic agents with full anti-inflammatory effects, such as 2,5-DMA, and non-anti-inflammatory agents with full psychedelic effects, such as DOTFM, are known.[98][99][100] Hence, the psychedelic and anti-inflammatory effects of serotonin 5-HT2A receptor agonists appear to be fully dissociable.[98][99][100] These effects appear to be mediated by different intracellular signaling pathways, although the exact pathways are unclear.[100]

Serotonin 5-HT2A receptor agonists with anti-inflammatory effects but reduced psychedelic effects, such as 2C-iBu (ELE-02), are under development for the potential treatment of inflammatory conditions.[101][102][103] They may also have applications in the treatment of neuroinflammation.[92][95] The anti-inflammatory effects of psychedelics might be involved in the claimed effects of psychedelic microdosing.[104][105] Relatedly, LSD microdosing is being studied in the treatment of Alzheimer's disease specifically for its anti-inflammatory effects.[106][107]

Full agonists

[edit]

Partial agonists

[edit]

Selective agonists

[edit]

Peripherally selective agonists

[edit]

One effect of 5-HT2A receptor activation is a reduction in intraocular pressure, and so 5-HT2A agonists can be useful for the treatment of glaucoma. This has led to the development of compounds such as AL-34662 that are hoped to reduce pressure inside the eyes but without crossing the blood–brain barrier and producing hallucinogenic side effects.[143] Animal studies with this compound showed it to be free of hallucinogenic effects at doses up to 30 mg/kg, although several of its more lipophilic analogues did produce the head-twitch response known to be characteristic of hallucinogenic effects in rodents.[144]

Antagonists

[edit]

Serotonin 5-HT2A receptor antagonists, including many atypical antipsychotics, more selective agents like pimavanserin, and certain antidepressants and hypnotics like trazodone, mirtazapine, tricyclic antidepressants, and hydroxyzine, are used in the treatment of psychiatric disorders and other conditions such as depression, anxiety, psychosis, and insomnia.[145][146][147] Ketanserin, a dual serotonin 5-HT2A receptor antagonist and α1-adrenergic receptor antagonist, is used as an antihypertensive agent.[148][147] The non-selective serotonin 5-HT2A receptor antagonist cyproheptadine is frequently used off-label to treat serotonin syndrome, albeit based on limited clinical evidence.[149][150][151] Serotonin 5-HT2A receptor antagonists like ketanserin have been used as psychedelic antidotes or "trip killers" to manage the hallucinogenic effects of serotonergic psychedelics.[152][153][154]

List of antagonists

[edit]

Peripherally selective antagonists

[edit]

Antagonists and cardiovascular disease

[edit]

Increased 5-HT2A expression is observed in patients with coronary thrombosis, and the receptor has been associated with processes that influence atherosclerosis.[166] As the receptor is present in coronary arteries[167] and capable of mediating vasoconstriction, 5-HT2A has also been linked to coronary artery spasms.[168] 5-HT antagonism, therefore, has potential in the prevention of cardiovascular disease, however, no studies have been published so far.[166]

Inverse agonists

[edit]

Positive allosteric modulators

[edit]

Positive allosteric modulators of the serotonin 5-HT2A receptor have been identified.[177][178] These include CTW0404 and CTW0419.[177][178] They selectively potentiated the serotonin 5-HT2A receptor without affecting the serotonin 5-HT2B and 5-HT2C receptors.[177][178] Unlike serotonin 5-HT2A receptor agonists, they did not substitute for the serotonergic psychedelic (R)-DOI in drug discrimination tests and did not produce the head-twitch response, suggesting that they lack psychedelic effects.[177][178] Instead, they blunted the (R)-DOI-induced head-twitch response.[178] The (R)-enantiomer of glaucine has also been reported to be a serotonin 5-HT2A receptor positive allosteric modulator.[179] A dual serotonin 5-HT2C and 5-HT2A receptor positive allosteric modulator is the oleamide analogue JPC0323.[180][181]

Functional selectivity

[edit]

5-HT2A-receptor ligands may differentially activate the transductional pathways (see above). Studies evaluated the activation of two effectors, PLC and PLA2, by means of their second messengers. Compounds displaying more pronounced functional selectivity are 2,5-DMA and 2C-N. The former induces IP accumulation without activating the PLA2 mediated response, while the latter elicits AA release without activating the PLC mediated response.[182]

Recent research has suggested potential signaling differences within the somatosensory cortex between 5-HT2A agonists that produce headshakes in the mouse and those that do not, such as lisuride, as these agents are also non-hallucinogenic in humans despite being active 5-HT2A agonists.[183][184] One known example of differences in signal transduction is between the two 5-HT2A agonists serotonin and DOI that involves differential recruitment of intracellular proteins called β-arrestins, more specifically arrestin beta 2.[185][186] Cyclopropylmethanamine derivatives such as (−)-19 have also been shown to act as 5-HT2A/2C agonists with functional selectivity for Gq-mediated signaling compared with β-arrestin recruitment.[187]

Serotonin-elevating drugs

[edit]

Besides direct serotonin 5-HT2A receptor agonists, many drugs elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors.[188][189] Examples include antidepressants and anxiolytics such as selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and serotonin precursors like tryptophan and 5-hydroxytryptophan (5-HTP).[188][189] In addition, serotonin releasing agents (SRAs), including appetite suppressants like fenfluramine and chlorphentermine and entactogens like MDMA, elevate serotonin levels and indirectly activate serotonin 5-HT2A receptors similarly.[190][191][192][193][194][195] Serotonin 5-HT2A receptor activation may be involved in the therapeutic effects of serotonin-elevating medications[188][189] and appears to be importantly involved in the subjective effects of SRAs like MDMA.[153] Serotonin-elevating drugs can cause serotonin syndrome under certain circumstances, for instance in overdose or with combination of multiple serotonergic drugs, and the serotonin 5-HT2A receptor appears to be a key serotonin receptor in mediating this syndrome.[196][197][198]

Methods to analyse the receptor

[edit]

The receptor can be analysed by neuroimaging, radioligand, genetic analysis, measurements of ion flows, and other ways.[citation needed]

Neuroimaging

[edit]

The 5-HT2A receptors may be imaged with PET-scanners using the fluorine-18-altanserin,[199] MDL 100,907[200] or [11C]Cimbi-36[108][201] radioligands that binds to the neuroreceptor, e.g., one study reported a reduced binding of altanserin particularly in the hippocampus in patients with major depressive disorder.[202]

Altanserin uptake decreases with age reflecting a loss of specific 5-HT2A receptors with age.[203][204][205]

Other

[edit]

Western blot with an affinity-purified antibody and examination of 5-HT2A receptor protein samples by electrophoresis has been described. Immunohistochemical staining of 5-HT2A receptors is also possible.[5]

Clinical significance

[edit]

Associations with psychiatric disorders

[edit]

Several studies have seen links between the -1438G/A polymorphism and mood disorders, such as major depressive disorder.[206] and a strong link with an odds ratio of 1.3 has been found between the T102C polymorphism and schizophrenia.[207]

The T102C polymorphism has also been studied in relation to suicide attempts, with a study finding excess of the C/C genotype among the suicide attempters.[208] A number of other studies were devoted to finding an association of the gene with schizophrenia, with diverging results.[209]

These individual studies may, however, not give a full picture: A review from 2007 looking at the effect of different SNPs reported in separate studies stated that "genetic association studies [of HTR2A gene variants with psychiatric disorders] report conflicting and generally negative results" with no involvement, small or a not replicated role for the genetic variant of the gene.[210]

Polymorphisms in the promoter gene coding Early growth response 3 (EGR3) are associated with schizophrenia. Studies have demonstrated a relationship between EGR3 and HTR2A, and schizophrenia-like behaviors in transgenic animals.[211][212] Exactly how these results translate over to further biopsychological understanding of schizophrenia is still widely debated.[213][214] There is some evidence that dysfunction of HTR2A can impact pharmacological interventions.[215]

Several studies have assessed a relationship between 5-hydroxytryptamine (serotonin) 2A receptor (5-HTR2A) gene polymorphisms with an increased risk of suicidal behavior. One study revealed that T102C polymorphism is associated with suicidal behavior[216] but other studies failed to replicate these findings and found no association between polymorphism and suicidal behavior.[217]

Treatment response

[edit]

Genetics seems also to be associated to some extent with the amount of adverse events in treatment of major depression disorder.[218]

Associations with substance abuse

[edit]

Polymorphisms in the 5-HT2A receptor coding gene HTR2A (rs6313 and s6311) have been shown to have conflicting associations with alcohol misuse. For example, A polymorphism in the 5-HT2A receptor coding gene HTR2A (rs6313) was reported to predict lower positive alcohol expectancy, higher refusal self-efficacy, and lower alcohol misuse in a sample of 120 young adults. However, this polymorphism did not moderate the linkages between impulsivity, cognition, and alcohol misuse.[219] There are conflicting results as other studies have found associations between T102C polymorphisms alcohol misuse.[220][221]

Drug impact on gene expression

[edit]

There is some evidence that methylation patterns may contribute to relapse behaviors in people who use stimulants.[222] In mice, psychotropic drugs such as DOI, LSD, DOM, and DOB which produced differing transcriptional patterns among several different brain regions.[212]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

5-HT2A receptor

View on Grokipedia
from Grokipedia
The 5-HT₂A receptor, also known as the 5-hydroxytryptamine receptor 2A, is a subtype of the serotonin receptor family classified as a class A (GPCR) with seven transmembrane domains and 471 , encoded by the HTR2A gene located on human chromosome 13q14.2. It serves as the primary target for the endogenous agonist serotonin (5-HT), mediating a wide array of physiological responses through Gq/11 protein coupling that activates , leading to (IP₃) production, diacylglycerol formation, and intracellular calcium mobilization. Expressed abundantly in the (CNS), particularly in cortical pyramidal neurons, it modulates key processes such as neuronal excitability, , , and mood, while in the periphery, it influences vascular contraction, platelet aggregation, and cardiovascular function. In the brain, the 5-HT₂A receptor is highly localized to layer V pyramidal cells of the , as well as regions like the hippocampus, , and , where it interacts with proteins such as PSD-95 for dendritic targeting and . Its activation enhances excitatory and has been linked to learning, , and emotional processing, with dysregulation implicated in psychiatric conditions including (via altered cortical expression), depression (reduced hippocampal binding), and obsessive-compulsive disorder (increased striatal binding). Peripherally, 5-HT₂A signaling contributes to , , and inflammatory responses associated with , underscoring its broader role in systemic . Pharmacologically, the 5-HT₂A receptor exhibits , where ligands bias specific downstream pathways—such as ERK1/2 activation or β-arrestin recruitment—allowing for tailored therapeutic effects; for instance, agonists like induce hallucinogenic states, while antagonists such as (pKᵢ 9.3–10.0) and (pKᵢ 8.1–9.7) are employed in antipsychotics to mitigate positive symptoms of . Regulation occurs via C-mediated desensitization and clathrin-dependent , with internalization recycling the receptor in approximately 2.5 hours following exposure. Ongoing emphasizes its potential in novel treatments for mood disorders and cognitive deficits, highlighting the receptor's paradoxical responses to chronic antagonism that can lead to either downregulation or upregulation depending on the ligand.

Discovery and History

Initial Identification

The classification of serotonin (5-hydroxytryptamine, 5-HT) receptors began in the early , shortly after serotonin's identification as a , with initial pharmacological studies distinguishing receptor subtypes based on their responses to agonists and antagonists in peripheral tissues. In 1953, John H. Gaddum described the antagonistic effects of diethylamide () on serotonin-mediated contractions in isolated gut preparations, suggesting a link between hallucinogens and serotonin signaling pathways. By the and , functional assays in and neuronal tissues led to a broad division into two subclasses: one resembling the "D" receptor (high affinity for serotonin, later termed 5-HT1) and another the "M" receptor (lower affinity for serotonin but sensitive to certain antagonists, later 5-HT2). This early framework, built on animal tissue experiments, set the stage for recognizing the 5-HT2 subclass as distinct from 5-HT1 by the , though molecular details remained elusive until binding techniques advanced. A pivotal pharmacological distinction of 5-HT2 receptors from 5-HT1 occurred in 1979 through radioligand binding studies in rat brain homogenates. Stephen J. Peroutka and demonstrated that tritiated serotonin ([³H]5-HT) preferentially labeled high-affinity sites (5-HT1), while [³H]spiperone—a with affinity for serotonin sites—bound to a separate population of lower-affinity serotonin receptors, designated 5-HT2. These sites exhibited distinct anatomical distributions, with 5-HT2 binding concentrated in cortical regions, and were sensitive to classic hallucinogens like , providing the first biochemical evidence for the 5-HT2 subclass as a unique entity. The molecular identity of the was confirmed in 1988 through of the rat Htr2a from a , using homology to the recently cloned 5-HT1C receptor (now known as 5-HT2C). Dolan B. Pritchett and colleagues expressed the cloned cDNA in mammalian cells, verifying its pharmacological profile as a serotonin receptor with characteristics matching the , including Gq/11-protein coupling that activates . This work established the (renamed from 5-HT2 to distinguish it from the 5-HT2C subtype) as a member of the G-protein-coupled receptor (GPCR) superfamily, with seven transmembrane domains typical of this family. The human HTR2A was subsequently cloned in 1990, showing high to the rat ortholog. Early animal studies in the and provided initial evidence linking the 5-HT2A receptor to the hallucinogenic effects of , though the specific subtype was not yet identified. In and models, induced behaviors such as head twitches in mice—later recognized as a proxy for 5-HT2A activation—and disrupted serotonin-mediated responses in the , supporting hypotheses that hallucinogens antagonize or mimic serotonin at central sites akin to the emerging 5-HT2 subclass. These observations, including 's blockade of serotonin-induced contractions in isolated brain tissues, foreshadowed the receptor's role in psychedelic pharmacology.

Key Developments

A major advancement in understanding the 5-HT2A receptor came from structural biology efforts in the early 2020s, building on homologous structures from related serotonin receptors. The first X-ray crystal structure of the human 5-HT2A receptor in an inactive conformation was determined in 2020, complexed with the inverse agonist methiothepin, revealing key features of the orthosteric binding pocket and the extracellular vestibule that stabilize the inactive state, including interactions with residues in transmembrane helices 3, 5, 6, and 7. This structure provided insights into antagonist binding and allosteric modulation, facilitating the design of selective ligands. Concurrently, a cryo-EM structure of the active-state 5-HT2A receptor bound to the hallucinogenic agonist 25-CN-NBOH, in complex with a Gq heterotrimer, highlighted conformational changes such as outward movement of transmembrane helix 6 and rearrangement of the toggle switch residue Trp3.41, essential for G protein coupling and signal transduction. The concept of biased agonism and functional selectivity at the 5-HT2A receptor emerged prominently in studies from 2008 to , demonstrating that ligands can preferentially activate specific signaling pathways despite similar binding affinities. For instance, hallucinogenic agonists like DOI were shown to recruit distinct subtypes and β-arrestin pathways compared to non-hallucinogenic agonists, leading to differential downstream effects such as head-twitch responses in animal models via selective Gq/11 coupling over G12/13. These findings underscored ligand-specific conformational dynamics, where agonists stabilize unique receptor states that bias toward activation or alternative effectors, influencing therapeutic outcomes in psychiatric disorders. Further structural progress in the involved cryo-EM determinations of active-state 5-HT2A complexes with psychedelic ligands, elucidating mechanisms of hallucinogenic action. In 2022, high-resolution structures of the 5-HT2A receptor bound to , the of , revealed how this induces distinct active conformations, including sodium pocket disruption and hydrogen bonding networks with Ser5.42 and Asn6.55 that promote engagement while differing from non-psychedelic agonists in extracellular loop 2 orientation. These structures highlighted psychedelic-specific interactions that may underlie and therapeutic effects in depression, contrasting with balanced agonists like serotonin. Building on this, 2023 cryo-EM structures with ligands like provided insights into allosteric modulation and subtype selectivity. Recent 2024-2025 studies have further explored intracellular 5-HT2A receptor localization and its role in sustained following psychedelic exposure, informing potential non-hallucinogenic therapeutic strategies. Integration of 5-HT2A research with has advanced through genetic association studies from 2015 to 2025, linking HTR2A polymorphisms to psychiatric conditions. A association study identified links between HTR2A variants, such as rs6314, and deficits in , suggesting roles in cognitive endophenotypes via altered receptor expression or signaling. Similarly, a 2020 gene-based analysis implicated HTR2A polymorphisms in antidepressant response variability in , with variants influencing treatment outcomes in therapy through modulated receptor density in . These genetic insights have informed approaches, emphasizing HTR2A's contributions to disease susceptibility and pharmacoresistance in and depression.

Molecular Biology

Gene Structure and Regulation

The HTR2A , which encodes the 5-HT2A receptor, is located on 13q14.2 at genomic coordinates 13:46,831,546-46,897,076 (GRCh38.p14), spanning approximately 66 kb. The gene consists of five exons in its current annotation, with the canonical transcript (ENST00000542664.4) utilizing four exons to produce a 471-amino-acid protein. This structure reflects updates from earlier annotations, incorporating additional exons identified through sequencing in tissue. Key polymorphisms in HTR2A include rs6311 (A-1438G) in the promoter region and rs6313 (T102C) in exon 1, which are in high and do not alter the protein sequence but are associated with variations in levels. Studies indicate that the rs6311 variant can influence binding affinity and promoter activity, potentially leading to reduced mRNA expression in certain genotypes. These single nucleotide polymorphisms (SNPs) have been linked to differential HTR2A transcript abundance across tissues, though results on expression effects remain somewhat inconsistent across and assays. Transcriptional regulation of HTR2A is mediated by its core promoter and upstream regulatory elements, including potential enhancer regions that form chromatin loops with the overlapping antisense gene HTR2A-AS1. The promoter polymorphism rs6311 modulates binding of transcription factors, affecting basal transcription rates. Epigenetic modifications, particularly at CpG sites in the promoter and 1 regions (e.g., near rs6311 and rs6313), inversely correlate with HTR2A expression; hypermethylation is observed in conditions like and autism, suppressing transcription. Alternative splicing of HTR2A primarily yields one functional protein-coding isoform from the canonical transcript, which includes all coding s and encodes the full-length receptor. However, additional splice variants exist, including a non-functional isoform lacking 1 that introduces a premature and triggers , as well as shorter isoforms (e.g., 308 or 110 ) from alternative usage, which are expressed at low levels and lack full receptor functionality. These variants arise mainly from splicing events at intron 1/ 2 boundaries, but the predominant isoform supports the receptor's physiological roles.

Protein Structure and Domains

The 5-HT2A receptor is a class A (GPCR) composed of 471 with a calculated molecular weight of approximately 52 kDa. Like other class A GPCRs, it features seven transmembrane α-helices (TM1–TM7) that span the plasma membrane, forming a characteristic barrel-like structure essential for recognition and . The receptor's includes an extracellular N-terminal domain, which is short and involved in access, and an intracellular C-terminal tail rich in sites that regulate receptor desensitization and internalization. The three intracellular loops (ICL1, ICL2, and ICL3) connect the transmembrane helices and play critical roles in G-protein coupling, with ICL3 being particularly important for interaction with heterotrimeric G proteins. The orthosteric binding pocket for serotonin is located deep within the transmembrane bundle, primarily formed by residues from TM3, TM5, TM6, and TM7. Key interactions include a between the protonated group of serotonin and Asp155^{3.32} in TM3, and hydrogen bonding between the NH and Ser242^{5.46} in TM5, stabilizing binding and contributing to receptor . These residues, conserved across serotonin receptors, enable specific recognition of serotonin and related ligands while allowing for pharmacological modulation by psychedelics and antipsychotics. Structural studies using cryo-electron microscopy (cryo-EM) and have revealed distinct conformational states of the 5-HT2A receptor. In the inactive (open) state, the binding pocket is accessible but the intracellular side remains constricted, preventing G-protein engagement; this conformation is often captured in antagonist-bound structures. binding, such as with serotonin or hallucinogens, induces an active (closed) state characterized by outward movement of TM6 and contraction of the orthosteric site, facilitating coupling. Intermediate states, observed in biased ligand complexes, highlight dynamic transitions that underlie .

Expression and Distribution

Tissue and Organ Distribution

The 5-HT2A receptor, encoded by the HTR2A gene, exhibits prominent expression in the , particularly within the brain, where it is highly enriched in cortical regions such as the prefrontal and frontal cortex, as well as the and . Moderate levels of expression are observed in peripheral tissues, including platelets, the , and cardiovascular structures like vascular cells and cardiac tissues. According to data from the Genotype-Tissue Expression (GTEx) project, median transcript per million (TPM) values for HTR2A are highest in the brain frontal cortex (BA9) at approximately 10 TPM, reflecting substantial neural involvement, while expression is notably lower in peripheral sites such as (0.62 TPM), colon transverse (0.41 TPM), and heart left ventricle (0.41 TPM). During development, HTR2A expression is upregulated in neural tissues, particularly in the embryonic , where activation of the 5-HT2A receptor promotes basal proliferation, contributing to cortical expansion. This pattern underscores its role in early , with detectable expression also in placental tissues that influence fetal neurodevelopment. In aging humans, 5-HT2A receptor density in the declines progressively, with an average reduction of about 17% per decade starting from age 20, though the rate may slow or plateau after age 60 in some studies. This age-related decrease is evident in cortical binding sites measured via . Expression patterns of the 5-HT2A receptor are broadly conserved between humans and , with high levels in the cortex and moderate presence in peripheral sites like the in both species.

Cellular and Subcellular Localization

The 5-HT2A receptor is predominantly expressed in pyramidal neurons within the and hippocampus, where it localizes to somatodendritic compartments and axons of these cells. In cortical pyramidal neurons specifically, the receptor is enriched in apical dendrites and a subset of dendritic spines, contributing to its role in neuronal signaling. Additionally, expression extends to in the , as evidenced by immunohistochemical detection of receptor-like immunoreactivity in glial fibrillary acidic protein-positive cells in the rat . Peripherally, the receptor is present in endothelial cells, particularly in vascular tissues such as the , where it influences renal vascular tone. Subcellularly, the 5-HT2A receptor primarily resides at the plasma membrane in cholesterol-rich lipid rafts and caveolae, facilitating interactions with signaling partners like Gαq and PLCβ. However, a significant proportion is also intracellular, localized to the Golgi apparatus and other endomembranes in cortical neurons, with less association to the plasma membrane compared to other GPCRs. Upon binding, the receptor undergoes dynamin-dependent , independent of β-arrestin in some cell types, leading to trafficking into sorting endosomes for potential recycling or lysosomal degradation. The receptor exhibits colocalization with the 5-HT2C subtype in certain neuronal populations, as shown by overlapping mRNA distributions in brain regions like the . Within dendrites, it displays both synaptic and extrasynaptic distribution: in spines, it colocalizes with postsynaptic density protein PSD-95, particularly in smaller spines, while also appearing in dendritic shafts. Postmortem studies of patients reveal pathological alterations, including reduced 5-HT2A receptor density in the frontal cortex (Brodmann's areas 8, 9, and 10), independent of treatment effects.

Pharmacology

Ligand Binding and Interactions

The 5-HT2A receptor, a , primarily interacts with serotonin (5-HT) as its endogenous orthosteric , exhibiting a binding affinity with a Ki value in the approximate range of 10-50 nM across various assay systems. This affinity is typically determined using radioligand binding assays, where is quantified via the Cheng-Prusoff for calculating the inhibition constant (Ki) from the IC50 value: Ki=IC501+[L]KdK_i = \frac{IC_{50}}{1 + \frac{[L]}{K_d}} Here, IC50 represents the concentration of the competing that displaces 50% of the bound radioligand, [L] is the concentration of the radioligand, and Kd is the of the radioligand. This equation assumes competitive binding and is widely applied in pharmacological studies of 5-HT2A receptor interactions to derive precise affinity metrics from experimental data. Agonists of the 5-HT2A receptor vary in efficacy and selectivity, influencing receptor activation through orthosteric binding. Full agonists, such as (), demonstrate high potency with a Ki of approximately 0.3-0.7 nM, enabling robust receptor stimulation comparable to serotonin. Partial agonists like exhibit lower maximal efficacy, acting as G protein-biased ligands with values around 17 nM at 5-HT2A receptors while showing reduced activation relative to full agonists. Selective agonists, such as the (R)- of DOI, display enhanced specificity for 5-HT2A over the related 5-HT2B subtype, with binding affinities in the sub-nanomolar range and minimal that supports targeted pharmacological probing. Although sarpogrelate was initially explored for peripheral restriction, it functions primarily as an rather than an at 5-HT2A receptors. Antagonists and inverse agonists bind competitively to the orthosteric site, blocking or reducing constitutive receptor activity. Typical antagonists like exhibit high affinity with a Ki of about 1 nM, effectively inhibiting serotonin-induced responses in binding and functional assays. These antagonists, such as ketanserin, also block the psychedelic effects of hallucinogens like LSD and psilocybin. Atypical antipsychotics such as also act as potent antagonists, with a Ki of approximately 0.4 nM at 5-HT2A receptors, contributing to their multi-receptor profile. Inverse agonists, including , not only block agonist binding (Ki ≈ 0.5 nM) but also suppress basal receptor signaling, distinguishing them from neutral antagonists through negative efficacy on constitutive activity. Allosteric modulators bind to distinct sites on the 5-HT2A receptor, altering orthosteric affinity or without directly competing for the primary binding pocket. Positive allosteric modulators, such as certain derivatives, enhance serotonin or agonist binding and potentiate downstream responses, though specific examples like PD-128907 primarily target and show limited direct allosteric effects at 5-HT2A. arises when ligands bias signaling pathways, such as favoring /11-mediated activation over β-arrestin recruitment; for instance, β-arrestin-biased agonists like 25CN-NBOH derivatives promote non-canonical pathways with reduced , influencing differential cellular outcomes.

Receptor Signaling Mechanisms

The 5-HT2A receptor, a prototypical (GPCR), primarily transduces signals through coupling to the Gq/11 family of heterotrimeric s. Upon binding, the receptor undergoes a conformational change that acts as a (GEF), catalyzing the exchange of GDP for GTP on the Gαq/11 subunit. This leads to dissociation of the into an active Gαq/11-GTP subunit and a Gβγ dimer, which together activate effector proteins such as phospholipase C-β (PLC-β). Activated PLC-β hydrolyzes (PIP2) in the plasma membrane to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses to the , where it binds IP3 receptors to release stored Ca2+ into the , elevating intracellular calcium levels and activating calcium-dependent processes. Meanwhile, DAG remains membrane-bound and recruits and activates (PKC), which phosphorylates downstream targets to modulate cellular responses such as and activity. The G-protein cycle can be summarized in the following simplified equation, reflecting the activation and deactivation steps: Inactive receptor+agonist+Gα-GDP⋅Gβγ⇌Active receptor⋅Gα-GTP⋅Gβγ→Gα-GTP+Gβγ+inactive receptor\text{Inactive receptor} + \text{agonist} + \text{G}_{\alpha\text{-}GDP} \cdot \text{G}_{\beta\gamma} \rightleftharpoons \text{Active receptor} \cdot \text{G}_{\alpha\text{-}GTP} \cdot \text{G}_{\beta\gamma} \rightarrow \text{G}_{\alpha\text{-}GTP} + \text{G}_{\beta\gamma} + \text{inactive receptor} Subsequent hydrolysis of GTP to GDP by the intrinsic GTPase activity of Gαq/11, often accelerated by regulators of G-protein signaling (RGS) proteins, allows reassociation of GαGDP with Gβγ and the receptor, terminating the signal. This cycle ensures transient and regulated activation of PLC and related effectors. Beyond the canonical Gq/11-PLC pathway, the 5-HT2A receptor engages alternative signaling mechanisms, including β-arrestin recruitment. Upon prolonged stimulation, β-arrestins (particularly β-arrestin 2) bind the phosphorylated receptor, sterically hindering further G-protein coupling and initiating (MAPK)/extracellular signal-regulated kinase (ERK) pathway activation. This β-arrestin-dependent ERK signaling occurs in endosomal compartments and contributes to mitogenic and transcriptional effects distinct from Gq/11-mediated responses. Biased further diversifies outcomes, as certain ligands (e.g., serotonin versus hallucinogens like DOI) preferentially stabilize conformations that favor either Gq/11-PLC or β-arrestin-ERK arms, influencing efficacy and therapeutic profiles. Receptor desensitization and regulation involve agonist-induced phosphorylation primarily at serine residues in the C-terminal tail and intracellular loops, mediated by G protein-coupled receptor kinases (GRKs) such as GRK2, though dependency on specific GRKs varies by cellular context. Phosphorylation promotes high-affinity binding of β-arrestins, which not only uncouple the receptor from G proteins but also facilitate clathrin- and dynamin-dependent internalization via endocytic vesicles. Internalized receptors may recycle to the plasma membrane after dephosphorylation or undergo lysosomal degradation, thereby attenuating signaling duration. Crosstalk with other GPCRs, such as through shared scaffold proteins or kinase cascades (e.g., RSK2-mediated attenuation), further modulates 5-HT2A responsiveness and integration into broader signaling networks.

Physiological Functions

Central Nervous System Roles

The 5-HT2A receptor plays a pivotal role in various central nervous system functions, particularly in modulating perception, emotion, cognition, and neural adaptability within key brain regions such as the cortex and prefrontal areas. Activation of this receptor by serotonergic ligands influences excitatory neurotransmission and synaptic dynamics, contributing to complex behavioral outcomes. Research has delineated specific mechanisms through which 5-HT2A signaling alters sensory processing, emotional regulation, executive processes, and structural remodeling of neural circuits. In the context of hallucinogenic effects, cortical 5-HT2A receptor activation leads to profound alterations in , primarily through interactions with metabotropic glutamate mGlu2 receptors forming a heterocomplex that recruits distinct G-protein signaling pathways. This interaction disrupts typical glutamate-mediated transmission, enhancing neuronal excitability and promoting hallucinatory perceptions by amplifying aberrant sensory signals in layer V pyramidal neurons of the prefrontal and visual cortices. Seminal studies using hallucinogens like DOI and demonstrate that this 5-HT2A-mGlu2 coupling is essential for the behavioral and electrophysiological hallmarks of , as disrupting the complex abolishes these effects without impacting non-hallucinogenic 5-HT2A . Regarding mood regulation, 5-HT2A receptors contribute to serotonin-mediated responses by facilitating rapid neuroplastic changes in mood-relevant circuits, particularly when activated by psychedelics that enhance synaptic connectivity in the . This activation promotes -like behaviors in models, potentially through downstream modulation of BDNF-TrkB pathways that counteract depressive states. In anxiety modulation, 5-HT2A signaling in prefrontal- circuits exerts an inhibitory influence, where higher receptor density in the medial correlates with reduced amygdala reactivity to stimuli, thereby dampening responses and facilitating emotional . The receptor also modulates , particularly and , via its expression on pyramidal neurons in the , where selective 5-HT2A agonism enhances delay-period activity and improves performance in spatial tasks in . This facilitatory role arises from increased persistent firing and gamma oscillations, underscoring 5-HT2A's contribution to executive function. In models, hypofunction of 5-HT2A signaling is linked to cognitive deficits, as blockade-induced augmentation of 5-HT2A expression mimics psychotic symptoms, while receptor antagonism exacerbates impairments in hypofunction states. Furthermore, 5-HT2A activation promotes by driving growth in cortical neurons, a process critical for synaptic remodeling and observed in psychedelics research from the . , a potent 5-HT2A , induces rapid and persistent increases in spine density and head diameter in the frontal cortex of mice, mediated through intracellular 5-HT2A receptors that engage TrkB and signaling pathways to enhance protein synthesis and ; recent 2025 studies further specify that this effect involves distinct types essential for the plasticity response. This mechanism, evidenced in both and models, highlights 5-HT2A's role in fostering structural plasticity that may underlie therapeutic effects in mood and cognitive disorders.

Peripheral and Systemic Effects

The 5-HT2A receptor plays a significant role in , particularly in mediating . In human , activation of 5-HT2A receptors on vascular cells induces contraction, contributing to reduced coronary blood flow and potential ischemic events. This vasoconstrictive effect is evident in responses to serotonin released from activated platelets during vascular injury, where 5-HT2A stimulation amplifies tone. Selective blockade of 5-HT2A receptors has been shown to enhance coronary blood flow by promoting release through compensatory activation in hypoperfused states. In the context of migraine pathophysiology, 5-HT2A receptor activation in the trigeminovascular system promotes neurogenic inflammation and . Stimulation of these receptors enhances production in endings and associated vasculature, facilitating signal transmission from peripheral afferents to central pathways. The 5-HT2A receptor influences gastrointestinal function primarily through its expression on cells, modulating motility and secretion. In the proximal and , 5-HT2A activation elicits contraction of longitudinal and circular , thereby regulating and transit. This receptor subtype is also implicated in secretory processes, with evidence from intestinal tissues showing 5-HT2A immunoreactivity on enterocytes and , supporting serotonin's role in fluid and balance. Regarding emesis control, antagonism of 5-HT2A receptors exhibits anti-emetic properties, as demonstrated by reduced motion- and cisplatin-induced in animal models pretreated with selective blockers. In hematological processes, 5-HT2A receptors on platelets promote aggregation and risk upon serotonin release from dense granules. Activation of platelet-surface 5-HT2A receptors augments shape change and granule secretion, synergizing with other agonists like to accelerate formation in arterial injury models. This mechanism contributes to occlusive events in diseased vessels, where 5-HT2A inhibition prevents serotonin-mediated amplification of platelet and . The 5-HT2A receptor exerts effects in immune cells, particularly macrophages, through biased that favors certain signaling pathways. In macrophages, selective 5-HT2A agonists reduce pro-inflammatory release, such as TNF-α and IL-6, by promoting β-arrestin recruitment over Gq-mediated responses, thereby dampening cascades in models of vascular and tissue . This has been observed in studies from 2019 to 2025, highlighting agonists like psychedelics that elicit outcomes independent of hallucinogenic effects, with recent work emphasizing β-arrestin-biased ligands for fine-tuning immune responses.

Analytical Methods

Imaging and Visualization Techniques

Imaging and visualization of the 5-HT2A receptor rely on a variety of techniques that enable spatial mapping and quantification in both living subjects and fixed tissues, providing insights into receptor distribution and dynamics. (PET) and (SPECT) are primary methods, utilizing selective radioligands to measure receptor binding potential (BP_ND), which reflects receptor and availability. These non-invasive approaches allow longitudinal studies in humans and animals, facilitating the assessment of receptor occupancy by endogenous ligands or therapeutics. Among the most established PET ligands for 5-HT2A imaging is [18F]altanserin, a fluorinated that exhibits high affinity and specificity for cortical receptors, enabling reliable quantification of BP_ND in regions such as the frontal and temporal cortices. In human studies, [18F]altanserin demonstrates neocortical BP_ND values typically ranging from 2.5 to 4.0, with lower binding in subcortical areas like the used as a reference region. Similarly, [11C]MDL 100907 (also known as [11C]M100907), a carbon-11 labeled , offers superior selectivity over [18F]altanserin by minimizing binding to sigma-1 receptors, achieving BP_ND values 4-6 times higher in neocortical regions compared to the in and human brains. SPECT ligands, though less common due to lower resolution, have also been explored for broader accessibility in clinical settings. These radiotracers have been pivotal in mapping 5-HT2A alterations in neuropsychiatric conditions, though interpretations focus on imaging metrics rather than diagnostic outcomes. Ex vivo, autoradiography provides high-resolution mapping of 5-HT2A distribution on tissue sections using tritiated ligands like [3H], which binds with nanomolar affinity to reveal receptor densities in postmortem and brains. This technique involves incubating cryosections with [3H], followed by exposure to generate silver patterns indicative of binding sites, often showing dense labeling in layer V pyramidal neurons of the cortex and . Quantitative analysis yields binding densities (B_max) around 500 fmol/mg protein in frontal cortex, allowing precise anatomical delineation that complements data. Unlike PET, autoradiography excels in subcellular resolution but requires fresh tissue and cannot capture dynamic processes. At the cellular level, fluorescence microscopy facilitates visualization of 5-HT2A localization in cultured cells and tissues through GFP-tagged receptors or immunolabeling with specific antibodies. of HEK293 or neuronal cell lines with C-terminal GFP-fused 5-HT2A constructs enables real-time tracking of receptor trafficking, such as agonist-induced internalization to endosomal compartments, observed via confocal imaging with green fluorescence colocalizing with lysosomal markers. Alternatively, antibodies targeting the receptor's N- or C-terminus, often conjugated to fluorophores like Alexa Fluor 488, allow immunocytochemical staining in fixed cultures, revealing plasma membrane and intracellular distributions without genetic modification. These methods are essential for studying receptor dynamics , bridging with spatial imaging. Recent advances in the have integrated (fMRI), particularly blood-oxygen-level-dependent (BOLD) contrast, to indirectly visualize downstream effects of 5-HT2A activation during psychedelic challenges. In clinical trials with agonists like , BOLD fMRI detects hyperconnectivity in the and , attributed to 5-HT2A-mediated neurovascular uncoupling, with signal changes up to 20-30% in responsive regions. These non-specific but receptor-linked hemodynamic responses complement direct ligand imaging by capturing real-time brain function alterations.

Biochemical and Functional Assays

Biochemical and functional assays are essential for quantifying the 5-HT2A receptor's binding affinity, , and downstream effects in isolated systems, providing foundational for understanding its molecular . These techniques enable precise measurement of interactions and signaling outputs without the complexities of intact tissues, often using recombinant expression systems in cell lines like HEK293 or cells. Radioligand binding assays remain a cornerstone for characterizing the 5-HT2A receptor's ligand affinity and density. In saturation binding experiments, tritiated or iodinated antagonists such as [³H]ketanserin are incubated with preparations from receptor-expressing cells, allowing determination of the (K_d) and maximum binding sites (B_max) through analysis. Scatchard plots, derived from these data, linearize the binding isotherm to visually assess receptor homogeneity and affinity, with typical K_d values for around 0.5-1 nM in human 5-HT2A-expressing membranes. These assays have been pivotal in identifying selective ligands and confirming receptor expression levels in various models. Functional assays directly evaluate 5-HT2A-mediated signaling, particularly its G_q/11 coupling leading to activation. For (IP1) accumulation, homogeneous time-resolved fluorescence (HTRF) assays detect IP1 levels in agonist-stimulated cells, with serotonin (5-HT) typically eliciting EC_{50} values of 10-50 nM in CHO cells stably expressing human 5-HT2A. via fluorescence imaging plate reader (FLIPR) systems measures transient intracellular Ca²⁺ mobilization using dyes like Fluo-4, confirming G_q pathway engagement with rapid onset kinetics. Additionally, cAMP ELISA kits assess potential , such as inhibitory effects on in certain cellular contexts, though 5-HT2A primarily drives excitatory responses. These methods have standardized high-throughput screening for agonists and antagonists. Reporter gene assays probe transcriptional consequences of 5-HT2A activation by coupling receptor signaling to expression under promoters like cyclic AMP (CRE). In such systems, 5-HT stimulation induces dose-dependent luminescence in HEK293 cells, with EC_{50} values mirroring native G_q responses and enabling quantification of biased agonism. For protein-protein interactions, bioluminescence resonance energy transfer (BRET) and Förster resonance energy transfer () techniques monitor 5-HT2A dimerization or associations with partners like β-arrestins, using fusion tags such as Renilla or GFP variants; these reveal constitutive activity and ligand-induced conformational changes with sub-nanomolar sensitivity. These assays have elucidated allosteric modulation and trafficking dynamics. CRISPR/Cas9 knockout models validate 5-HT2A-specific contributions by ablating the receptor gene (HTR2A) in cell lines or murine models, followed by phenotypic with re-expression. In HEK293 , loss of 5-HT-induced IP1 accumulation confirms on-target effects, while embryonic fibroblasts from Htr2a^{-/-} animals show abolished head-twitch responses to psychedelics, linking receptor absence to behavioral deficits. These genetic tools, combined with Western blotting for protein confirmation, ensure assay specificity and have advanced structure-function studies. For validation, such models can integrate with techniques to correlate molecular changes with localization.

Clinical and Therapeutic Implications

Associations with Disorders

The 5-HT2A receptor, encoded by the HTR2A gene, has been implicated in the pathophysiology of through altered receptor expression. While some early studies suggested associations between HTR2A polymorphisms such as rs6311 (-1438A/G) and risk, meta-analyses do not confirm a significant link with disease susceptibility. (PET) studies using ligands like [18F]altanserin have consistently demonstrated reduced cortical 5-HT2A receptor binding in individuals with compared to healthy controls, suggesting a downregulation or dysfunction in receptor density that may underlie psychotic symptoms. This reduced binding is observed particularly in prefrontal and temporal cortical regions, correlating with symptom severity and cognitive deficits. In and anxiety disorders, epigenetic modifications of the HTR2A gene, including promoter hypermethylation, are linked to decreased 5-HT2A receptor expression, potentially exacerbating mood dysregulation. Studies in peripheral blood and brain tissue have identified hypermethylation at specific CpG sites in the HTR2A promoter among individuals with severe depression, correlating with lower mRNA levels and heightened symptom severity. This epigenetic silencing may contribute to treatment resistance, as variations in HTR2A, including polymorphisms affecting promoter activity, have been associated with poorer response to selective serotonin inhibitors (SSRIs) in patients with depression and anxiety. For instance, certain HTR2A genotypes predict reduced efficacy of SSRIs, possibly due to impaired postsynaptic serotonin signaling that hinders antidepressant-induced . HTR2A polymorphisms have shown mixed associations with obsessive-compulsive disorder (OCD) in meta-analyses, with some evidence of links in males but no consistent gain-of-function variants identified. PET imaging supports elevated 5-HT2A binding in regions like the among OCD patients, consistent with hyperactivity in serotonin-mediated pathways. While peripheral 5-HT2A signaling is implicated in pathophysiology through vascular effects, meta-analyses of HTR2A polymorphisms find no consistent association with heightened susceptibility to aura or headache episodes. Substance abuse disorders involving serotonergic drugs exhibit alterations in 5-HT2A expression, particularly upregulation following chronic exposure to psychedelics and changes in gene regulation from agents like . Chronic administration of 5-HT2A agonists, such as psychedelics, leads to upregulated HTR2A in responsive neuronal populations, potentially reinforcing addictive behaviors through enhanced receptor-mediated plasticity in reward circuits. In users, PET studies indicate alterations in 5-HT2A density, with evidence of downregulation in recent users and potential compensatory changes during , alongside transcriptional changes in serotonin-related genes that may perpetuate craving and relapse. These adaptations highlight the receptor's role in the neurobiological sequelae of .

Drug Targeting and Therapies

The 5-HT2A receptor serves as a key target for pharmacological modulation in psychiatric disorders, primarily through antagonism by atypical antipsychotics. and , both potent 5-HT2A inverse agonists, contribute to their efficacy in treating by reducing positive symptoms such as hallucinations and delusions, alongside D2 receptor blockade. These agents exhibit higher affinity for 5-HT2A receptors compared to typical antipsychotics, which may underlie their improved side-effect profile, including lower risk of . , a selective 5-HT2A without significant antagonism, was approved by the FDA in 2016 specifically for managing hallucinations and delusions in , offering a safer alternative for patients sensitive to side effects. Agonism at the 5-HT2A receptor has emerged as a therapeutic strategy in psychedelics for mood disorders. , a serotonergic agonist with high selectivity for 5-HT2A, has demonstrated rapid and sustained effects in clinical trials for , with phase 2 and 3 studies from 2018 to 2025 showing significant symptom reduction lasting up to six months post-administration. As of November 2025, phase 3 trials such as Compass Pathways' COMP004 have reported positive results, with the FDA expected to review for approval imminently. The FDA granted designation to formulations in 2018 for , accelerating development based on preliminary evidence of superior efficacy over existing s. Beyond , derivatives of the selective 5-HT2A agonist DOI, such as (R)-DOI, exhibit potent anti-inflammatory properties by suppressing tumor necrosis factor-alpha (TNF-α) production and other proinflammatory markers in preclinical models of inflammatory diseases, including and , at doses below those inducing behavioral effects. Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), functions as a 5-HT2A receptor antagonist, which contributes to its therapeutic effects including promotion of anxiolysis, relaxation, improved sleep quality, and reduction of anxiety symptoms, particularly in patients with depression accompanied by anxiety and insomnia. Genetic predictors of treatment response enhance personalized approaches to 5-HT2A-targeted therapies. The T102C polymorphism (rs6313) in the HTR2A gene, which encodes the 5-HT2A receptor, has been associated with variability in response to selective serotonin reuptake inhibitors (SSRIs) for depression, with the C linked to poorer remission rates in meta-analyses of diverse populations. for this variant may guide SSRI dosing or selection, as carriers of the T/T show faster symptom improvement and higher efficacy in randomized trials. Safety considerations in 5-HT2A modulation include risks from off-target effects on the related . Prolonged agonism at , often seen in non-selective serotonergic drugs targeting 5-HT2A, promotes cardiac and through fibroblast proliferation and extracellular matrix deposition, as evidenced by cases with derivatives. To mitigate this, peripherally selective 5-HT2A antagonists like sarpogrelate have been developed, which inhibit platelet aggregation and in vascular tissues without penetration, providing cardiovascular protection in conditions such as and post-thrombotic syndromes.

References

  1. https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=6
  2. https://www.ncbi.nlm.nih.gov/books/NBK1853/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC3110590/
  4. https://www.sciencedirect.com/science/article/abs/pii/B9780444641250000050
  5. https://www.ncbi.nlm.nih.gov/books/NBK28234/
  6. https://www.acnp.org/g4/GN401000039/Ch039.html
  7. https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.70050
  8. https://www.cell.com/cell/fulltext/S0092-8674(20)31066-7
  9. https://www.sciencedirect.com/science/article/abs/pii/S0014299908007954
  10. https://pubs.acs.org/doi/10.1021/ja508394x
  11. https://www.science.org/doi/10.1126/science.abl8615
  12. https://www.cell.com/cell/fulltext/S0092-8674(23)00442-1
  13. https://www.nature.com/articles/s41593-024-01699-5
  14. https://www.nature.com/articles/npp20155
  15. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.559601/full
  16. https://www.ncbi.nlm.nih.gov/gene/3356
  17. https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102468
  18. https://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000102468;r=13:46831546-46897076;t=ENST00000542664
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC4702415/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3582836/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC3044825/
  22. https://genesight.com/white-papers/get-to-know-a-gene-htr2a/
  23. https://updatepublishing.com/journal/index.php/rib/article/download/9081/6401
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4073158/
  25. https://www.nature.com/articles/s41598-020-78809-x
  26. https://www.uniprot.org/uniprotkb/P28223/entry
  27. https://bmcgenomdata.biomedcentral.com/articles/10.1186/s12863-015-0325-6
  28. https://go.drugbank.com/polypeptides/P28223
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC2629388/
  30. https://www.sciencedirect.com/science/article/pii/S1570963923000286
  31. https://pubmed.ncbi.nlm.nih.gov/17715398/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC12491688/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC7593816/
  34. https://www.researchgate.net/figure/Structure-of-5-HT2AR-a-5-HT2ARris-b-5-HT2ARzot-5-HT2AR-is-shown-in-pink-a-and-cyan_fig6_330890712
  35. https://www.proteinatlas.org/ENSG00000102468-HTR2A/tissue
  36. https://www.nature.com/articles/s41598-020-78595-6
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC2790184/
  38. https://gtexportal.org/home/gene/ENSG00000102468
  39. https://pubmed.ncbi.nlm.nih.gov/33080227/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC4199868/
  41. https://psychiatryonline.org/doi/10.1176/appi.ajp.159.3.430
  42. https://pubmed.ncbi.nlm.nih.gov/11870007/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2928707/
  44. https://pubmed.ncbi.nlm.nih.gov/10379914/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC2780750/
  46. https://doi.org/10.1016/S0006-8993(00)03150-4
  47. https://rrtjournal.biomedcentral.com/articles/10.1186/s41100-020-00268-x
  48. https://www.science.org/doi/10.1126/science.adf0435
  49. https://pubmed.ncbi.nlm.nih.gov/8799865/
  50. https://pubmed.ncbi.nlm.nih.gov/8885041/
  51. https://pmc.ncbi.nlm.nih.gov/articles/PMC6298744/
  52. https://pubmed.ncbi.nlm.nih.gov/9600588/
  53. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0075426
  54. https://pubmed.ncbi.nlm.nih.gov/17031071/
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC9004607/
  56. https://www.nature.com/articles/s41467-023-44016-1
  57. https://pubmed.ncbi.nlm.nih.gov/33278025/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC11206742/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC10724237/
  60. https://pubmed.ncbi.nlm.nih.gov/7938165
  61. https://doi.org/10.1073/pnas.0708862105
  62. https://www.sciencedirect.com/science/article/pii/S2211383525004575
  63. https://doi.org/10.1021/bi035061z
  64. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2015.00225/full
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC3064746/
  66. https://www.sciencedirect.com/science/article/pii/S0006899324004803
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC2758681/
  68. https://www.jneurosci.org/content/22/7/2843
  69. https://www.sciencedirect.com/science/article/abs/pii/S0149763415300245
  70. https://www.nature.com/articles/s41398-022-01930-0
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC6082376/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC11566025/
  73. https://pubmed.ncbi.nlm.nih.gov/10374714/
  74. https://pubmed.ncbi.nlm.nih.gov/10996601/
  75. https://pubmed.ncbi.nlm.nih.gov/15572052/
  76. https://pubmed.ncbi.nlm.nih.gov/12482207/
  77. https://pubmed.ncbi.nlm.nih.gov/12466231/
  78. https://pubmed.ncbi.nlm.nih.gov/9430791/
  79. https://pubmed.ncbi.nlm.nih.gov/11960784/
  80. https://pubmed.ncbi.nlm.nih.gov/7780647/
  81. https://pubmed.ncbi.nlm.nih.gov/19922435/
  82. https://pubmed.ncbi.nlm.nih.gov/16409475/
  83. https://pubmed.ncbi.nlm.nih.gov/8836449/
  84. https://pubs.acs.org/doi/10.1021/acsptsci.3c00297
  85. https://www.nature.com/articles/s41598-019-49987-0
  86. https://www.sciencedirect.com/science/article/pii/S0031699725074678
  87. https://www.cambridge.org/core/product/2271446B6789F3010D4E08138D4C4F29
  88. https://pubmed.ncbi.nlm.nih.gov/9443763/
  89. https://pubmed.ncbi.nlm.nih.gov/9826230/
  90. https://www.sciencedirect.com/science/article/abs/pii/S1053811911007610
  91. https://www.sciencedirect.com/science/article/abs/pii/000689939090274F
  92. https://pubmed.ncbi.nlm.nih.gov/16206185/
  93. https://www.pnas.org/doi/pdf/10.1073/pnas.212517999
  94. https://pubmed.ncbi.nlm.nih.gov/27598719/
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC8137947/
  96. https://pubmed.ncbi.nlm.nih.gov/17899021/
  97. https://www.sciencedirect.com/science/article/pii/S0924977X19317250
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC5720374/
  99. https://www.mdpi.com/1424-8247/18/9/1360
  100. https://pmc.ncbi.nlm.nih.gov/articles/PMC446220/
  101. https://pubmed.ncbi.nlm.nih.gov/32734920/
  102. https://pubmed.ncbi.nlm.nih.gov/15801987/
  103. https://pubmed.ncbi.nlm.nih.gov/25019276/
  104. https://www.omim.org/entry/182135
  105. https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-016-0711-0
  106. https://www.mdpi.com/1422-0067/25/1/241
  107. https://www.vumc.org/cowan-lab/mdma-toxicity-pet
  108. https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.02-0502com
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC3154112/
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC5543701/
  111. https://www.ncbi.nlm.nih.gov/books/NBK519503/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC11420065/
  113. https://www.ncbi.nlm.nih.gov/books/NBK557712/
  114. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC12030455/
  116. https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Announces-Publication-of-Results-from-COMP004-Study-on-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx
  117. https://www.explorationpub.com/uploads/Article/A1006105/1006105.pdf
  118. https://pubmed.ncbi.nlm.nih.gov/24098382/
  119. https://www.ncbi.nlm.nih.gov/books/NBK519059/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC3326907/
  121. https://pubmed.ncbi.nlm.nih.gov/19361869/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC3500192/
  123. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-025-07301-5
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC10944580/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC11073569/
  126. https://www.sciencedirect.com/science/article/abs/pii/S016372580400107X
  127. https://www.mdpi.com/1424-8247/14/12/1268
Add your contribution
Related Hubs
User Avatar
No comments yet.